<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03113955</url>
  </required_header>
  <id_info>
    <org_study_id>S2382</org_study_id>
    <nct_id>NCT03113955</nct_id>
  </id_info>
  <brief_title>STOPPER CHINA:With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</brief_title>
  <official_title>A Single-arm Trial of Transcatheter Arterial Chemoembolization With Tandem Microspheres in the Treatment of Localized Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston Scientific Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston Scientific Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres in
      the Treatment of Localized Hepatocellular Carcinoma
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It is a prospective, single-arm, multicenter study. The primary effectiveness endpoint for
      this clinical trial is 6-month overall objective tumor response (ORR).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 24, 2017</start_date>
  <completion_date type="Anticipated">May 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The objective response rate</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>The objective response rate measured by MRI, CT, RECIST v 1.1 and mRECIST</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>TTP is measured by RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>Tumor Response is measured by MRI, CT , RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion Progression-Free</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>PPF is measured by MRI, CT , RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>from first TACE to 12 months</time_frame>
    <description>Overall survival is measured by RECIST v 1.1 and mRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events rate</measure>
    <time_frame>At 1,3,6,12 months</time_frame>
    <description>documentation of all adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">109</enrollment>
  <condition>Localized Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>single -arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A Single-arm Trial of Transcatheter Arterial Chemoembolization with Tandem Microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Tandem Microsphere loaded with Epirubicin</intervention_name>
    <description>The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)</description>
    <arm_group_label>single -arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient is able to provide informed consent and must sign the Institutional Review
             Board/Ethics Committee (IRB/EC) approved Informed Consent Form.

          2. Male or female of age â‰¥ 18 years.

          3. Confirmed diagnosis of HCC according to the diagnostic criteria included in the
             management guideline issued by China's Ministry of Health in 2011.

          4. HCC is diagnosed for the first time or recurrence of tumor after radical treatment.

          5. Single tumor less than 10cm in diameter or multiple tumors with less than 10 in
             numbers and less than 10cm in total diameter.

          6. no previous chemotherapy, radiotherapy or transarterial embolization (with or without
             chemotherapy)

          7. Preserved liver function (Child-Pugh A or B).

          8. ECOG Performance Status 0 or 1.

        Exclusion Criteria:

          1. Presence of extra-hepatic spread of disease or arteriovenuous fistula

          2. Macrovascular invasion portal vein at entry into the study

          3. Prior intra-arterial embolization or chemotherapy or systemic therapy for treatment of
             HCC

          4. Any contraindication for TACE treatment

          5. Any contraindication for Epirubicin administration

          6. Advanced liver disease (bilirubin levels &gt;3 mg/dl, AST or ALT &gt;5 times upper limit of
             normal)

          7. Renal failure or insufficient renal function

          8. Advanced tumoral disease (vascular invasion or extrahepatic spread, or diffuse HCC,
             defined as &gt;50% liver involvement
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Suqiong Wang</last_name>
    <phone>+86 2161419759</phone>
    <email>suqiong.wang@bsci.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongda Hospital Affiliated Southeast University</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaojun Teng, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengjing Hospital Affiliated China Medical University</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhaoyu Liu, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Guoliang Shao, Dr</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2017</study_first_submitted>
  <study_first_submitted_qc>April 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2017</study_first_posted>
  <last_update_submitted>February 24, 2018</last_update_submitted>
  <last_update_submitted_qc>February 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

